Publications by authors named "Chara Mastrokalou"
Article Synopsis
- Decitabine (DAC) is a drug that helps treat solid tumors, but more research is needed to understand how safe and effective it is.
- Researchers tried using DAC with breast cancer cells to see if a special protein called DCK could make DAC work better, but it didn't change the DNA levels or kill more cancer cells.
- DAC caused some genes to become more or less active in the cells, showing that it can change how cancer cells behave, but some bad genes were still active, which could make treatment harder.
Acquired drug resistance and metastasis in breast cancer (BC) are coupled with epigenetic deregulation of gene expression. Epigenetic drugs, aiming to reverse these aberrant transcriptional patterns and sensitize cancer cells to other therapies, provide a new treatment strategy for drug-resistant tumors. Here we investigated the ability of DNA methyltransferase (DNMT) inhibitor decitabine (DAC) to increase the sensitivity of BC cells to anthracycline antibiotic doxorubicin (DOX).
View Article and Find Full Text PDFProtein-protein interactions are the quintessence of physiological activities, but also participate in pathological conditions. Amyloid formation, an abnormal protein-protein interaction process, is a widespread phenomenon in divergent proteins and peptides, resulting in a variety of aggregation disorders. The complexity of the mechanisms underlying amyloid formation/amyloidogenicity is a matter of great scientific interest, since their revelation will provide important insight on principles governing protein misfolding, self-assembly and aggregation.
View Article and Find Full Text PDF